Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

of LX1031 has progressed with the goal of achieving a lower and less frequent dosing regimen that will provide a similar safety and efficacy profile to that observed with the original formulation.  In addition, LX1033, a back-up compound that is approximately 10-fold more potent than LX1031, has completed IND-enabling studies.  It is anticipated that LX1033 will commence Phase 1 testing in the first quarter of 2011.
  • Rheumatoid Arthritis:  Lexicon completed dosing in the expanded Phase 2a clinical trial of its drug candidate for rheumatoid arthritis, LX2931, an inhibitor of sphingosine-1-phosphate lyase.  Top-line data from the study, which enrolled 208 patients and was conducted at multiple centers in the United States and Eastern Europe, are expected to be available by the end of the year.
  • Carcinoid Syndrome:  Enrollment in both the United States and Europe is continuing in the Phase 2a trials for LX1032, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels. Preliminary data from both trials are expected to be available in the first half of 2011.

    • Financial Results and EventsOn July 30, 2010, Lexicon exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.  Pursuant to the amended terms of the purchase option, Lexicon paid Symphony Icon Holdings LLC $10 million and agr
    '/>"/>

    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
    2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
    3. Lexicon to Present at Two Major Healthcare Investor Conferences
    4. Lexicon Announces Pricing of Common Stock in Public Offering
    5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
    6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
    7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
    9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
    10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
    11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2013)... 2013 NANONEX CORPORATION, a pioneer ... today announced the successful delivery and installation of ... NX-M200B, to a major Japanese manufacturing company. ... production-ready, advanced nanoimprint lithography tool that has the ... substrate sizes and types. Based on Nanonex inventions ...
    (Date:5/21/2013)... May 21, 2013 Possible mold re-infestation in ... according to a report from eagletribune.com posted May 14, 2013, ... case the result is positive, My Cleaning Products offered a ... chemical ingredients. , It was said in the Eagle Tribune ... in the campus sparked after a first-grade classroom was closed ...
    (Date:5/21/2013)... The Formulate Fusion Fabric Display Kit ... marketing teams looking for a fully-functional package for their trade ... you’ll need to put together a stunning and eye-catching trade ... number of displays and accessories that can be quickly assembled ... feet in size. These components vary from kit to kit, ...
    (Date:5/20/2013)... 21, 2013 Grace Century , ... “game-changing” life science and health related private equity projects, ... its International Project Team. Dergham's expertise in finance and ... depth to Grace Century as it continues to look ... Ms. Dergham holds both an under graduate degree from ...
    Breaking Biology Technology:Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Dalia Dergham Joins Grace Century FZ LLC International Project Team 2
    ... Adhere to Sleep Apnea TreatmentSAN CARLOS, Calif., Feb. ... study has shown their patients comply with Obstructive ... the industry average.Analysis performed in October 2008 looked ... testing and treatment with Positive Airway Pressure beginning ...
    ... 3 BioMarin Pharmaceutical Inc. (Nasdaq: ... 2 multi-center, randomized, double-blind, placebo-controlled clinical study of ... (PAD). There was no statistical significance observed ... endpoint of the study, peak walking time (PWT), ...
    ... Bulletin Board: AGGX.OB) is a New York-based biotechnology company ... proteins for the discovery and development of anti-angiogenic drugs ... presented animal data at two recent scientific ... molecule candidate drug AGX51 to mitigate tumor formation and ...
    Cached Biology Technology:SleepQuest Compliance Again Doubles Industry Average 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 3Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 4AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 2AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 3
    (Date:5/20/2013)... effect of physical education (PE) on child weight, but ... the amount of time that elementary schoolchildren spent in ... study represents some of the first evidence of a ... forthcoming in the Journal of Health Economics . ... be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The research ...
    (Date:5/20/2013)... (May 20, 2013) - A novel vaccine ... the groundbreaking research that will be unveiled at the ... (NBC). The meeting takes place Monday, May 20 - ... and Marina. , "The main goal of a ... against a pathogen that causes the disease", explained Dr. ...
    (Date:5/19/2013)... have engineered a strain of electricity-producing bacteria that can ... and carbon dioxide as its sole source of carbon. ... their findings at the 113th General Meeting of the ... result of current production solely on hydrogen," says Amit ... his co-authors are part of the Lovley Lab Group ...
    Breaking Biology News(10 mins):Gym class reduces probability of obesity, study finds for first time 2Germ-fighting vaccine system makes great strides in delivery 2
    ... days shortening toward winter, many people will begin to experience ... About 6 percent of the U.S. population suffers ... begins in the fall and continues through winter. Sufferers may ... the morning. The disorder, which is not well understood, ...
    ... look at that cheap piece of scrap iron before you ... good use for it. Someday soon, much of the world ... engineering, recently concluded a five-year research project in which he ... million pounds of iron to detoxify pollutants in industrial wastewater. ...
    ... and simulation experts from Rhode Island Hospital discuss ... manuscripts appearing in the November 2008 issue of ... The articles describe how simulation centers, along with ... for dynamic, complex and unanticipated medical situations in ...
    Cached Biology News:Seasonal affective disorder may be linked to genetic mutation, study suggests 2A green future for scrap iron 2A green future for scrap iron 3Rhode Island Hospital simulation center examines benefits and applications of medical simulation 2Rhode Island Hospital simulation center examines benefits and applications of medical simulation 3
    Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
    ... The steadylite plus assay ... High assay sensitivity, Designed for ... Suitable for higher density microplates ... plates, Odor free, Convenient storage ...
    Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
    Functionally tested for consistent G-banding of chromosomes....
    Biology Products: